Background pattern
IRBESARTAN ZENTIVA 75 mg FILM-COATED TABLETS

IRBESARTAN ZENTIVA 75 mg FILM-COATED TABLETS

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use IRBESARTAN ZENTIVA 75 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Irbesartan Zentiva 75 mg film-coated tablets

Irbesartan

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist, even if you think they are not serious. See section 4.

Contents of the pack

  1. What is Irbesartan Zentiva and what is it used for
  2. What you need to know before you take Irbesartan Zentiva
  3. How to take Irbesartan Zentiva
  4. Possible side effects
  5. Storage of Irbesartan Zentiva
  6. Contents of the pack and other information

1. What is Irbesartan Zentiva and what is it used for

Irbesartan Zentiva belongs to a group of medicines called angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that causes blood vessels to constrict, leading to an increase in blood pressure.

Irbesartan Zentiva prevents angiotensin-II from binding to its receptors, relaxing blood vessels and reducing blood pressure. Irbesartan Zentiva slows down the progression of kidney damage in patients with high blood pressure and type 2 diabetes.

Irbesartan Zentiva is used in adult patients

  • to treat high blood pressure (essential hypertension)
  • to protect the kidneys in patients with high blood pressure, type 2 diabetes, and evidence of kidney damage.

2. What you need to know before you take Irbesartan Zentiva

Do not take Irbesartan Zentiva

  • if you are allergicto irbesartan or any of the other ingredients of this medicine (listed in section 6)
  • if you are pregnant more than 3 months. (In any case, it is better to avoid taking this medicine also at the start of your pregnancy – see section Pregnancy)
  • if you have diabetes or kidney problemsand are being treated with a blood pressure medicine containing aliskiren.

Warnings and precautions

Consult your doctor before starting to take Irbesartan Zentiva and if any of the following apply to you:

  • if you have excessive vomiting or diarrhea
  • if you have kidney problems
  • if you have heart problems
  • if you are taking Irbesartan Zentiva for diabetic kidney disease. In this case, your doctor may regularly perform blood tests, especially to measure potassium levels in case of impaired kidney function
  • if you are going to have surgery(surgical procedure) or if you are going to be given anesthetics
    • if you are taking any of the following medicines used to treat high blood pressure:
  • a medicine called an angiotensin-converting enzyme inhibitor (ACE inhibitor) (e.g. enalapril, lisinopril, ramipril), especially if you have kidney problems related to diabetes
  • aliskiren

Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.

See also the information under the heading “Do not take Irbesartan Zentiva”.

If you are pregnant, think you might be pregnant, or plan to become pregnant, inform your doctor. Irbesartan Zentiva is not recommended during the first three months of pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby (see section Pregnancy).

Children and adolescents

This medicine should not be used in children and adolescents as the safety and efficacy have not been fully established.

Taking Irbesartan Zentiva with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Your doctor may need to change your dose and/or take other precautions:

If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Irbesartan Zentiva” and “Warnings and precautions”).

You may need to have blood tests if you are taking:

  • potassium supplements
  • potassium-sparing diuretics (a type of diuretic)
  • medicines containing lithium

If you are using a type of painkiller called non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.

Taking Irbesartan Zentiva with food and drink

Irbesartan Zentiva can be taken with or without food.

Pregnancy and breastfeeding

Pregnancy

You should inform your doctor if you are pregnant, think you might be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking Irbesartan Zentiva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead. Irbesartan Zentiva should not be taken during the first three months of pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby.

Breastfeeding

Inform your doctor if you are breastfeeding or about to start breastfeeding as Irbesartan Zentiva is not recommended for use during breastfeeding. Your doctor may decide to give you a different treatment that is more suitable for you, especially if you are breastfeeding a newborn or premature infant.

Driving and using machines

It is unlikely that Irbesartan Zentiva will affect your ability to drive or use machines. However, during treatment of high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, consult your doctor before driving or using machines.

Irbesartan Zentiva contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3. How to take Irbesartan Zentiva

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Method of administration

Irbesartan Zentiva is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g. one glass of water). Irbesartan Zentiva can be taken with or without food. You should try to take your daily dose at the same time each day. It is important that you continue to take this medicine until your doctor tells you to stop.

  • Patients with high blood pressure

The usual dose is 150 mg once daily (two tablets a day). Depending on the response to blood pressure, this dose may be increased to 300 mg once daily (four tablets a day).

  • Patients with high blood pressure and type 2 diabetes with kidney damage

In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney disease is 300 mg once daily (four tablets a day). Your doctor may advise a lower dose, especially when starting treatment, in certain patients such as those on hemodialysis or elderly patients over 75 years.

The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.

Use in children and adolescents

Irbesartan Zentiva should not be given to children under 18 years. If a child swallows several tablets, contact your doctor immediately.

If you take more Irbesartan Zentiva than you should

If you accidentally take too many tablets, contact your doctor immediately.

If you forget to take Irbesartan Zentiva

If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some of these side effects can be serious and may need medical attention.

As with similar medicines, rare cases of skin allergic reactions (rash, urticaria) as well as localized swelling of the face, lips, and/or tongue have been reported in patients treated with irbesartan. If you think you have had an allergic reaction, stop taking Irbesartan Zentiva and see a doctor immediately.

The following side effects have been reported:

Very common: may affect more than 1 in 10 people

Common: may affect up to 1 in 10 people

Uncommon: may affect up to 1 in 100 people

The following side effects have been reported in clinical trials:

  • Very common (may affect more than 1 in 10 people): if you have high blood pressure and type 2 diabetes with kidney damage, blood tests may show high levels of potassium.
  • Common (may affect up to 1 in 10 people): dizziness, nausea/vomiting, fatigue, and blood tests may show high levels of an enzyme that measures muscle and heart function (creatine kinase). In patients with high blood pressure and type 2 diabetes with kidney damage, dizziness (especially when standing up), low blood pressure (especially when standing up), muscle or joint pain, and decreased levels of a protein found in red blood cells (hemoglobin)
  • Uncommon (may affect up to 1 in 100 people): rapid heartbeat, flushing, cough, diarrhea, indigestion/heartburn, sexual dysfunction (sexual problems), and chest pain.

Since the marketing of Irbesartan Zentiva, the following side effects have been reported:

Frequency not known: cannot be estimated from the available data

The following side effects have been reported: feeling dizzy, headache, altered taste, ringing in the ears, muscle cramps, muscle and joint pain, reduced number of platelets, abnormal liver function, high levels of potassium in the blood, kidney failure, inflammation of small blood vessels, mainly in the skin area (a condition known as leucocytoclastic vasculitis), and severe allergic reactions (anaphylactic shock). Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Irbesartan Zentiva

Keep out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Do not store above 30°C.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Irbesartan Zentiva contains

  • The active substance is irbesartan. Each film-coated tablet contains 75 mg of irbesartan.
  • The other ingredients are lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, hypromellose, colloidal silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, carnauba wax. See section 2 “Irbesartan Zentiva contains lactose”.

Appearance and packaging

Irbesartan Zentiva 75 mg film-coated tablets are white or almost white, biconvex, and oval-shaped, with a heart-shaped indentation on one side and the number 2871 engraved on the other side.

Irbesartan Zentiva 75 mg film-coated tablets are available in blister packs of 14, 28, 30, 56, 84, 90, or 98 film-coated tablets. They are also available in packs of 56 x 1 film-coated tablet containing unit-dose blisters for hospital use.

Not all pack sizes may be marketed.

Marketing authorisation holder

Zentiva k.s.

U kabelovny 130

102 37 Prague 10

Czech Republic

Manufacturer

SANOFI WINTHROP INDUSTRIE

1, rue de la Vierge

Ambarès & Lagrave

F-33565 Carbon Blanc Cedex - France

SANOFI WINTHROP INDUSTRIE

30-36 Avenue Gustave Eiffel, BP 7166

F-37071 Tours Cedex 2 - France

You can get more information about this medicine by contacting the representative of the marketing authorisation holder.

België/Belgique/Belgien

Zentiva, k.s.

Tel/Tel: +32 280 86 420

PV-Belgium@zentiva.com

Lietuva

Zentiva, k.s.

Tel: +370 52152025

PV-Lithuania@zentiva.com

България

Zentiva, k.s.

Тел: + 359 2 805 72 08

PV-Bulgaria@zentiva.com

Luxembourg/Luxemburg

Zentiva, k.s.

Tél/Tel: +352 208 82330

PV-Luxembourg@zentiva.com

Ceská republika

Zentiva, k.s.

Tel: +420 267 241 111

PV-Czech-Republic@zentiva.com

Magyarország

Zentiva, k.s.

Tel.: +36 165 55 722

PV-Hungary@zentiva.com

Danmark

Zentiva, k.s.

Tlf: +45 787 68 400

PV-Denmark@zentiva.com

Malta

Zentiva, k.s.

Tel: +356 277 82 052

PV-Malta@zentiva.com

Deutschland

Zentiva Pharma GmbH

Tel: +49 (0) 800 53 53 010

PV-Germany@zentiva.com

Nederland

Zentiva, k.s.

Tel: +31 202 253 638

PV-Netherlands@zentiva.com

Eesti

Zentiva, k.s.

Tel: +372 52 70308

PV-Estonia@zentiva.com

Norge

Zentiva, k.s.

Tlf: +47 219 66 203

PV-Norway@zentiva.com

Ελλάδα

Zentiva, k.s.

Τηλ: +30 211 198 7510

PV-Greece@zentiva.com

Österreich

Zentiva, k.s.

Tel: +43 720 778 877

PV-Austria@zentiva.com

España

Zentiva, k.s.

Tel: +34 931 815 250

PV-Spain@zentiva.com

Polska

Zentiva Polska Sp. z o.o.

Tel: + 48 22 375 92 00

PV-Poland@zentiva.com

France

Zentiva France

Tél: +33 (0) 800 089 219

PV-France@zentiva.com

Portugal

Zentiva Portugal, Lda

Tel: +351210601360

PV-Portugal@zentiva.com

Hrvatska

Zentiva, k.s.

Tel: +385 155 17 772

PV-Croatia@zentiva.com

România

S.C. ZENTIVA S.A.

Tel: +40 021 317 31 36

PV-Romania@zentiva.com

Ireland

Zentiva, k.s.

Tel: +353 766 803 944

PV-Ireland@zentiva.com

Slovenija

Zentiva, k.s.

Tel: +386 360 00 408

PV-Slovenia@zentiva.com

Ísland

Zentiva, k.s.

Sími: +354 539 0650

PV-Iceland@zentiva.com

Slovenská republika

Zentiva, a.s.

Tel: +421 2 3918 3010

PV-Slovakia@zentiva.com

Italia

Zentiva Italia S.r.l.

+39-02-38598801

PV-Italy@zentiva.com

Suomi/Finland

Zentiva, k.s.

Puh/Tel: +358 942 598 648

PV-Finland@zentiva.com

Κύπρος

Zentiva, k.s.

Τηλ: +357 240 30 144

PV-Cyprus@zentiva.com

Sverige

Zentiva, k.s.

Tel: +46 840 838 822

PV-Sweden@zentiva.com

Latvija

Zentiva, k.s.

Tel: +371 67893939

PV-Latvia@zentiva.com

United Kingdom

Zentiva Pharma UK Limited

Tel: +44 (0) 845 372 7101

PV-United-Kingdom@zentiva.com

Date of last revision of this leaflet

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe